Is the High-Risk Strategy to Prevent Cardiovascular Disease Equitable?

被引：0
|
作者：
Kildemoes, Helle Wallach [1 ]
Diderichsen, Finn
Lange, Theis
Andersen, Morten [2 ]
机构：
[1] Univ Copenhagen, Ctr Healthy Ageing, Copenhagen, Denmark
[2] Karolinska Inst, Ctr Pharmacoepidemiol, Stockholm, Sweden
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2011年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
57
引用
收藏
页码：S25 / S26
页数：2
相关论文
共 50 条
  • [1] Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study
    Helle Wallach-Kildemoes
    Finn Diderichsen
    Allan Krasnik
    Theis Lange
    Morten Andersen
    BMC Public Health, 12
  • [2] Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study
    Wallach-Kildemoes, Helle
    Diderichsen, Finn
    Krasnik, Allan
    Lange, Theis
    Andersen, Morten
    BMC PUBLIC HEALTH, 2012, 12
  • [3] Prognostic Variation Among Very High-Risk and High-Risk Individuals With Atherosclerotic Cardiovascular Disease
    Mok, Yejin
    Ballew, Shoshana H.
    Stacey, Richard Brandon
    Rossi, Joseph
    Koton, Silvia
    Kucharska-Newton, Anna M.
    Chang, Patricia P.
    Coresh, Josef
    Rosamond, Wayne
    Matsushita, Kunihiro
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (03) : 346 - 348
  • [4] Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
    Lincoff, A. Michael
    Nicholls, Stephen J.
    Riesmeyer, Jeffrey S.
    Barter, Philip J.
    Brewer, H. Bryan
    Fox, Keith A. A.
    Gibson, C. Michael
    Granger, Christopher
    Menon, Venu
    Montalescot, Gilles
    Rader, Daniel
    Tall, Alan R.
    McErlean, Ellen
    Wolski, Kathy
    Ruotolo, Giacomo
    Vangerow, Burkhard
    Weerakkody, Govinda
    Goodman, Shaun G.
    Conde, Diego
    McGuire, Darren K.
    Nicolau, Jose C.
    Leiva-Pons, Jose L.
    Pesant, Yves
    Li, Weimin
    Kandath, David
    Kouz, Simon
    Tahirkheli, Naeem
    Mason, Denise
    Nissen, Steven E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (20): : 1933 - 1942
  • [5] Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
    Lincoff, A. M.
    Nicholls, S. J.
    Riesmeyer, J. S.
    Barter, P. J.
    Brewer, H. B.
    Fox, K. A. A.
    JOURNAL OF VASCULAR SURGERY, 2017, 66 (04) : 1302 - 1302
  • [6] Heart and kidney disease: a cardiovascular high-risk constellation
    Schunk, Stefan J.
    Speer, Thimoteus
    Fliser, Danilo
    HERZ, 2021, 46 (03) : 206 - 211
  • [7] Effect of evacetrapib on cardiovascular outcomes in patients with high-risk cardiovascular disease
    Aronow, Wilbert S.
    JOURNAL OF THORACIC DISEASE, 2017, 9 (07) : 1822 - 1825
  • [8] Influenza Vaccine for Patients With High-risk Cardiovascular Disease
    Patel, Manish M.
    Uyeki, Timothy M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (01): : 33 - 35
  • [9] Appropriate strategies for the cardiovascular "disease". High-risk patients
    Caballero Gueeto, Juliana
    Ulecia Martinez, Miguel Angel
    Gonzalez Cocina, Emilio
    Lagares Carballo, Manuel
    MEDICINA CLINICA, 2009, 133 (07): : 261 - 271
  • [10] Screening for High-Risk Cardiovascular Disease A Challenge for the Guidelines
    Smith, Sidney C., Jr.
    ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (01) : 40 - 42
12345